Table 1 Basophil surface marker expression relative to SLE disease activity
From: Prostaglandin D2 amplifies lupus disease through basophil accumulation in lymphoid organs
Chemokine or cytokine receptor analyzed | CD # | Ligand(s) | Normalized expression levels (to CT mean) on basophils from: Mean (±SE, n, P Mann−Whitney test vs CT) | |||
|---|---|---|---|---|---|---|
Healthy controls (controls, CT) | Inactive SLE patients (SLEDAI ≤ 1) | Mild SLE patients (1 < SLEDAI ≤ 4) | Active SLE patients (SLEDAI > 4) | |||
CCR1 | CD191 | CCL3, 5, 7, 23 | 1 (±0.14, 13, 1) | 1.013 (±0.17, 15, 0.78) | 1.199 (±0.13, 8, 0.40) | 1.11 (±0.18, 19, 1) |
CCR2 | CD192 | CCL2, 7, 8, 13, 16 | 1 (±0.11, 30, 1) | 1.04 (±0.15, 19, 0.89) | 1.03 (±0.25, 14, 0.57) | 1.04 (±0.2, 20, 0.58) |
CCR3 | CD193 | Eotaxin | 1 (±0.10, 53, 1) | 0.8529 (±0.10, 10, 0.4578) | 1.229 (±0.27, 14, 0.5876) | 0.9214 (±0.07, 38, 0.9951) |
CCR4 | CD194 | CCL2, 4, 5, 17, 22 | UD | UD | UD | UD |
CCR5 | CD195 | CCL5, 3, 4, 3L1 | 1 (±0.14, 6, 1) | 0.7726 (±0.09, 5, 0.43) | 1.377 (±0.42, 3, 0.38) | 1.031 (±0.19, 7, 0.94) |
CCR6 | CD196 | CCL20 | UD | UD | UD | UD |
CCR7 | CD197 | CCL19, 21 | UD | UD | UD | UD |
CXCR1 | CD181 | IL-8 | 1 (±0.12, 25, 1) | 1.104 (±0.21, 6, 0.63) | 1.197 (±0.17, 6, 0.28) | 1.187 (±0.27, 13, 0.90) |
CXCR2 | CD182 | IL-8, CXCL1, 2, 3, 5 | 1 (±0.04, 53, 1) | 1.181 (±0.12, 27, 0.85) | 0.9324 (±0.08, 15, 0.21) | 1.053 (±0.12, 37, 0.22) |
CXCR4 | CD184 | CXCL12 | 1 (±0.05, 95, 1) | 1.221** (±0.09, 32, 0.0034) | 1.562** (±0.21, 24, 0.0011) | 2.503**** (±0.28, 70, <0.0001) |
PTGDR-2 (CRTH2) | CD294 | PGD2 | 1 (±0.09, 101, 1) | 1.730*** (±0.18, 49, 0.0003) | 1.889** (±0.32, 34, 0.0045) | 1.314* (±0.14, 78, 0.0251) |
Endolyn | CD164 | CXCR4 | 1 (±0.07, 62, 1) | 0.8793 (±0.10, 16, 0.5792) | 1.064 (±0.17, 11, 0.6424) | 1.458**(±0.13, 45, 0.0025) |
TSLP-R | — | TSLP | UD | UD | UD | UD |
IL33-R | T1/ST2 | IL-33 | UD | UD | UD | UD |
